G03 Corpus callosal atrophy in Huntington's disease
Identifieur interne : 002E31 ( Istex/Corpus ); précédent : 002E30; suivant : 002E32G03 Corpus callosal atrophy in Huntington's disease
Auteurs : He Crawford ; Nz Hobbs ; J. Cole ; Em Rees ; G. Owen ; Dr Langbehn ; C. Frost ; B. Landwehrmeyer ; R. Reilmann ; D. Craufurd ; Jc Stout ; A. Durr ; B. Leavitt ; Ra Roos ; Sj Tabrizi ; Ri ScahillSource :
- Journal of Neurology, Neurosurgery & Psychiatry [ 0022-3050 ] ; 2012-09.
English descriptors
- KwdEn :
- 1radiology department, 1ucl institute, 7genetic medicine, Aberrant brain development, Abnormal brain development, Abstract table, Aphp hopital, Atrophy rates, Background research, Baseline volumes, Behavioural parameters, Brain growth, Brain morphology, Brain structure, British columbia, Central manchester university hospitals, Cerebral lobes, Cerebral structure, Chdi foundation, Clinical impairment, Clinical measures, Clinical psychobiology, Cognitive decline, Conclusions measurement, Corpus callosal atrophy, Corpus callosum, Cortical alterations, Cortical areas, Current study, Disease onset, Early disease stages, Early neurobiological changes, Foundation trust, Funding helen crawford, Gene nonexpanded, Global measures, Globus pallidus, Grey matter, Health sciences centre, Healthy control, Healthy control subjects, Huntington disease imaging, Huntington disease mutation carriers, Imaging biomarker, Important component, Important role, Increase sensitivity, Interhemispheric connections, Interhemispheric relationships, Internal medicine, Iowa, Iowa city, Irccs neuromed, Irccs santa lucia foundation, Iron concentration, Iron content, Large cohort, Leiden university, London school, Longitudinal change, Magnetic susceptibility, Matrix size, Medical genetics, Medical statistics, Methodological approach, Methods children ages, Monash university, Multiecho relaxometry, Mutation carriers, Nding treatments, Neurol neurosurg psychiatry september, Neurology, Novel segmentation technique, Parietal lobe, Posterior tracts, Premanifest gene carriers, Premanifest subjects, Presymptomatic subjects, Public health, Putamen, Rare diseases center, Regional tissues, Research purposes, Same protocol, Segmentation protocol, Striatal structure, Striatal volume, Study iron distribution, Tesla siemens scanner, Total brain tissue, Total brain tissue volumes, Tropical medicine, University college london, Useful measure, Ventricular volume, Volume change, Volume loss, Volumetric measurements, Voxel size, Washington university, White matter volume.
- Teeft :
- 1radiology department, 1ucl institute, 7genetic medicine, Aberrant brain development, Abnormal brain development, Abstract table, Aphp hopital, Atrophy rates, Background research, Baseline volumes, Behavioural parameters, Brain growth, Brain morphology, Brain structure, British columbia, Central manchester university hospitals, Cerebral lobes, Cerebral structure, Chdi foundation, Clinical impairment, Clinical measures, Clinical psychobiology, Cognitive decline, Conclusions measurement, Corpus callosal atrophy, Corpus callosum, Cortical alterations, Cortical areas, Current study, Disease onset, Early disease stages, Early neurobiological changes, Foundation trust, Funding helen crawford, Gene nonexpanded, Global measures, Globus pallidus, Grey matter, Health sciences centre, Healthy control, Healthy control subjects, Huntington disease imaging, Huntington disease mutation carriers, Imaging biomarker, Important component, Important role, Increase sensitivity, Interhemispheric connections, Interhemispheric relationships, Internal medicine, Iowa, Iowa city, Irccs neuromed, Irccs santa lucia foundation, Iron concentration, Iron content, Large cohort, Leiden university, London school, Longitudinal change, Magnetic susceptibility, Matrix size, Medical genetics, Medical statistics, Methodological approach, Methods children ages, Monash university, Multiecho relaxometry, Mutation carriers, Nding treatments, Neurol neurosurg psychiatry september, Neurology, Novel segmentation technique, Parietal lobe, Posterior tracts, Premanifest gene carriers, Premanifest subjects, Presymptomatic subjects, Public health, Putamen, Rare diseases center, Regional tissues, Research purposes, Same protocol, Segmentation protocol, Striatal structure, Striatal volume, Study iron distribution, Tesla siemens scanner, Total brain tissue, Total brain tissue volumes, Tropical medicine, University college london, Useful measure, Ventricular volume, Volume change, Volume loss, Volumetric measurements, Voxel size, Washington university, White matter volume.
Abstract
Background Research into Huntington's disease (HD) has revealed white-matter loss in individuals more than 10 years prior to predicted disease onset, focused around the striatum, corpus callosum (CC) and posterior white-matter tracts. Degeneration of the CC is of interest since it provides interhemispheric connections to cortical areas known to be affected in HD. Aims This study aims to investigate the utility of volumetric measurements of the CC in HD using a novel segmentation technique, multiple time-points and a large well-characterised cohort. Structure-function relationship in the CC will also be explored. Methods Volumetric 3T MRI from controls, premanifest gene carriers and early HD subjects enrolled in the TRACK-HD study will be analysed at baseline and 24 months. The CC will be delineated using a semi-automated segmentation protocol. Differences in baseline volumes and atrophy rates between groups will be examined, as well as correlations between volume loss and clinical impairment. Results Preliminary analysis of a subset of subjects indicates that early HD subjects have reduced CC volume compared with controls and premanifest subjects (p<0.001). Increased longitudinal CC volume change was found in early HD subjects, compared with controls (p<0.001). Interestingly there was significant difference in longitudinal change between controls and premanifest subjects close to disease onset (p<0.05). This work will be extended to include multi-site data and correlations between atrophy and clinical and cognitive decline. Conclusions Measurement of CC atrophy may have potential as an imaging biomarker for HD and may prove useful for exploring interhemispheric structure-function relationships. Funding Helen Crawford is supported by the CHDI Foundation, a not for profit organisation dedicated to finding treatments for HD.
Url:
DOI: 10.1136/jnnp-2012-303524.83
Links to Exploration step
ISTEX:F5CA874DE78DE98E65D05D4283D1B3CC98696C71Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>G03 Corpus callosal atrophy in Huntington's disease</title><author><name sortKey="Crawford, He" sort="Crawford, He" uniqKey="Crawford H" first="He" last="Crawford">He Crawford</name><affiliation><mods:affiliation>UCL Institute of Neurology, University College London, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Hobbs, Nz" sort="Hobbs, Nz" uniqKey="Hobbs N" first="Nz" last="Hobbs">Nz Hobbs</name><affiliation><mods:affiliation>UCL Institute of Neurology, University College London, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Cole, J" sort="Cole, J" uniqKey="Cole J" first="J" last="Cole">J. Cole</name><affiliation><mods:affiliation>UCL Institute of Neurology, University College London, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Rees, Em" sort="Rees, Em" uniqKey="Rees E" first="Em" last="Rees">Em Rees</name><affiliation><mods:affiliation>UCL Institute of Neurology, University College London, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Owen, G" sort="Owen, G" uniqKey="Owen G" first="G" last="Owen">G. Owen</name><affiliation><mods:affiliation>UCL Institute of Neurology, University College London, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Langbehn, Dr" sort="Langbehn, Dr" uniqKey="Langbehn D" first="Dr" last="Langbehn">Dr Langbehn</name><affiliation><mods:affiliation>Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Biostatistics (Secondary), University of Iowa, Iowa City, Iowa, USA</mods:affiliation></affiliation></author><author><name sortKey="Frost, C" sort="Frost, C" uniqKey="Frost C" first="C" last="Frost">C. Frost</name><affiliation><mods:affiliation>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Landwehrmeyer, B" sort="Landwehrmeyer, B" uniqKey="Landwehrmeyer B" first="B" last="Landwehrmeyer">B. Landwehrmeyer</name><affiliation><mods:affiliation>Department of Neurology, Ulm University, Ulm, Germany</mods:affiliation></affiliation></author><author><name sortKey="Reilmann, R" sort="Reilmann, R" uniqKey="Reilmann R" first="R" last="Reilmann">R. Reilmann</name><affiliation><mods:affiliation>Department of Neurology, University of Münster, Münster, Germany</mods:affiliation></affiliation></author><author><name sortKey="Craufurd, D" sort="Craufurd, D" uniqKey="Craufurd D" first="D" last="Craufurd">D. Craufurd</name><affiliation><mods:affiliation>Genetic Medicine, University of Manchester, Manchester Academic Health Sciences Centre and Central Manchester University Hospitals NHS Foundation Trust, St Mary's Hospital, Manchester, UK</mods:affiliation></affiliation></author><author><name sortKey="Stout, Jc" sort="Stout, Jc" uniqKey="Stout J" first="Jc" last="Stout">Jc Stout</name><affiliation><mods:affiliation>School of Psychology and Psychiatry, Monash University, Victoria, Australia</mods:affiliation></affiliation></author><author><name sortKey="Durr, A" sort="Durr, A" uniqKey="Durr A" first="A" last="Durr">A. Durr</name><affiliation><mods:affiliation>Department of Genetics and Cytogenetics, and INSERM UMR S679, APHP Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Leavitt, B" sort="Leavitt, B" uniqKey="Leavitt B" first="B" last="Leavitt">B. Leavitt</name><affiliation><mods:affiliation>Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation></author><author><name sortKey="Roos, Ra" sort="Roos, Ra" uniqKey="Roos R" first="Ra" last="Roos">Ra Roos</name><affiliation><mods:affiliation>Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Tabrizi, Sj" sort="Tabrizi, Sj" uniqKey="Tabrizi S" first="Sj" last="Tabrizi">Sj Tabrizi</name><affiliation><mods:affiliation>UCL Institute of Neurology, University College London, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Scahill, Ri" sort="Scahill, Ri" uniqKey="Scahill R" first="Ri" last="Scahill">Ri Scahill</name><affiliation><mods:affiliation>UCL Institute of Neurology, University College London, London, UK</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F5CA874DE78DE98E65D05D4283D1B3CC98696C71</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1136/jnnp-2012-303524.83</idno><idno type="url">https://api.istex.fr/document/F5CA874DE78DE98E65D05D4283D1B3CC98696C71/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002E31</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002E31</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">G03 Corpus callosal atrophy in Huntington's disease</title><author><name sortKey="Crawford, He" sort="Crawford, He" uniqKey="Crawford H" first="He" last="Crawford">He Crawford</name><affiliation><mods:affiliation>UCL Institute of Neurology, University College London, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Hobbs, Nz" sort="Hobbs, Nz" uniqKey="Hobbs N" first="Nz" last="Hobbs">Nz Hobbs</name><affiliation><mods:affiliation>UCL Institute of Neurology, University College London, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Cole, J" sort="Cole, J" uniqKey="Cole J" first="J" last="Cole">J. Cole</name><affiliation><mods:affiliation>UCL Institute of Neurology, University College London, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Rees, Em" sort="Rees, Em" uniqKey="Rees E" first="Em" last="Rees">Em Rees</name><affiliation><mods:affiliation>UCL Institute of Neurology, University College London, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Owen, G" sort="Owen, G" uniqKey="Owen G" first="G" last="Owen">G. Owen</name><affiliation><mods:affiliation>UCL Institute of Neurology, University College London, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Langbehn, Dr" sort="Langbehn, Dr" uniqKey="Langbehn D" first="Dr" last="Langbehn">Dr Langbehn</name><affiliation><mods:affiliation>Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Biostatistics (Secondary), University of Iowa, Iowa City, Iowa, USA</mods:affiliation></affiliation></author><author><name sortKey="Frost, C" sort="Frost, C" uniqKey="Frost C" first="C" last="Frost">C. Frost</name><affiliation><mods:affiliation>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Landwehrmeyer, B" sort="Landwehrmeyer, B" uniqKey="Landwehrmeyer B" first="B" last="Landwehrmeyer">B. Landwehrmeyer</name><affiliation><mods:affiliation>Department of Neurology, Ulm University, Ulm, Germany</mods:affiliation></affiliation></author><author><name sortKey="Reilmann, R" sort="Reilmann, R" uniqKey="Reilmann R" first="R" last="Reilmann">R. Reilmann</name><affiliation><mods:affiliation>Department of Neurology, University of Münster, Münster, Germany</mods:affiliation></affiliation></author><author><name sortKey="Craufurd, D" sort="Craufurd, D" uniqKey="Craufurd D" first="D" last="Craufurd">D. Craufurd</name><affiliation><mods:affiliation>Genetic Medicine, University of Manchester, Manchester Academic Health Sciences Centre and Central Manchester University Hospitals NHS Foundation Trust, St Mary's Hospital, Manchester, UK</mods:affiliation></affiliation></author><author><name sortKey="Stout, Jc" sort="Stout, Jc" uniqKey="Stout J" first="Jc" last="Stout">Jc Stout</name><affiliation><mods:affiliation>School of Psychology and Psychiatry, Monash University, Victoria, Australia</mods:affiliation></affiliation></author><author><name sortKey="Durr, A" sort="Durr, A" uniqKey="Durr A" first="A" last="Durr">A. Durr</name><affiliation><mods:affiliation>Department of Genetics and Cytogenetics, and INSERM UMR S679, APHP Hôpital de la Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Leavitt, B" sort="Leavitt, B" uniqKey="Leavitt B" first="B" last="Leavitt">B. Leavitt</name><affiliation><mods:affiliation>Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada</mods:affiliation></affiliation></author><author><name sortKey="Roos, Ra" sort="Roos, Ra" uniqKey="Roos R" first="Ra" last="Roos">Ra Roos</name><affiliation><mods:affiliation>Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Tabrizi, Sj" sort="Tabrizi, Sj" uniqKey="Tabrizi S" first="Sj" last="Tabrizi">Sj Tabrizi</name><affiliation><mods:affiliation>UCL Institute of Neurology, University College London, London, UK</mods:affiliation></affiliation></author><author><name sortKey="Scahill, Ri" sort="Scahill, Ri" uniqKey="Scahill R" first="Ri" last="Scahill">Ri Scahill</name><affiliation><mods:affiliation>UCL Institute of Neurology, University College London, London, UK</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title><title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title><idno type="ISSN">0022-3050</idno><idno type="eISSN">1468-330X</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2012-09">2012-09</date><biblScope unit="volume">83</biblScope><biblScope unit="issue">Suppl 1</biblScope><biblScope unit="page" from="A27">A27</biblScope></imprint><idno type="ISSN">0022-3050</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-3050</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1radiology department</term><term>1ucl institute</term><term>7genetic medicine</term><term>Aberrant brain development</term><term>Abnormal brain development</term><term>Abstract table</term><term>Aphp hopital</term><term>Atrophy rates</term><term>Background research</term><term>Baseline volumes</term><term>Behavioural parameters</term><term>Brain growth</term><term>Brain morphology</term><term>Brain structure</term><term>British columbia</term><term>Central manchester university hospitals</term><term>Cerebral lobes</term><term>Cerebral structure</term><term>Chdi foundation</term><term>Clinical impairment</term><term>Clinical measures</term><term>Clinical psychobiology</term><term>Cognitive decline</term><term>Conclusions measurement</term><term>Corpus callosal atrophy</term><term>Corpus callosum</term><term>Cortical alterations</term><term>Cortical areas</term><term>Current study</term><term>Disease onset</term><term>Early disease stages</term><term>Early neurobiological changes</term><term>Foundation trust</term><term>Funding helen crawford</term><term>Gene nonexpanded</term><term>Global measures</term><term>Globus pallidus</term><term>Grey matter</term><term>Health sciences centre</term><term>Healthy control</term><term>Healthy control subjects</term><term>Huntington disease imaging</term><term>Huntington disease mutation carriers</term><term>Imaging biomarker</term><term>Important component</term><term>Important role</term><term>Increase sensitivity</term><term>Interhemispheric connections</term><term>Interhemispheric relationships</term><term>Internal medicine</term><term>Iowa</term><term>Iowa city</term><term>Irccs neuromed</term><term>Irccs santa lucia foundation</term><term>Iron concentration</term><term>Iron content</term><term>Large cohort</term><term>Leiden university</term><term>London school</term><term>Longitudinal change</term><term>Magnetic susceptibility</term><term>Matrix size</term><term>Medical genetics</term><term>Medical statistics</term><term>Methodological approach</term><term>Methods children ages</term><term>Monash university</term><term>Multiecho relaxometry</term><term>Mutation carriers</term><term>Nding treatments</term><term>Neurol neurosurg psychiatry september</term><term>Neurology</term><term>Novel segmentation technique</term><term>Parietal lobe</term><term>Posterior tracts</term><term>Premanifest gene carriers</term><term>Premanifest subjects</term><term>Presymptomatic subjects</term><term>Public health</term><term>Putamen</term><term>Rare diseases center</term><term>Regional tissues</term><term>Research purposes</term><term>Same protocol</term><term>Segmentation protocol</term><term>Striatal structure</term><term>Striatal volume</term><term>Study iron distribution</term><term>Tesla siemens scanner</term><term>Total brain tissue</term><term>Total brain tissue volumes</term><term>Tropical medicine</term><term>University college london</term><term>Useful measure</term><term>Ventricular volume</term><term>Volume change</term><term>Volume loss</term><term>Volumetric measurements</term><term>Voxel size</term><term>Washington university</term><term>White matter volume</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>1radiology department</term><term>1ucl institute</term><term>7genetic medicine</term><term>Aberrant brain development</term><term>Abnormal brain development</term><term>Abstract table</term><term>Aphp hopital</term><term>Atrophy rates</term><term>Background research</term><term>Baseline volumes</term><term>Behavioural parameters</term><term>Brain growth</term><term>Brain morphology</term><term>Brain structure</term><term>British columbia</term><term>Central manchester university hospitals</term><term>Cerebral lobes</term><term>Cerebral structure</term><term>Chdi foundation</term><term>Clinical impairment</term><term>Clinical measures</term><term>Clinical psychobiology</term><term>Cognitive decline</term><term>Conclusions measurement</term><term>Corpus callosal atrophy</term><term>Corpus callosum</term><term>Cortical alterations</term><term>Cortical areas</term><term>Current study</term><term>Disease onset</term><term>Early disease stages</term><term>Early neurobiological changes</term><term>Foundation trust</term><term>Funding helen crawford</term><term>Gene nonexpanded</term><term>Global measures</term><term>Globus pallidus</term><term>Grey matter</term><term>Health sciences centre</term><term>Healthy control</term><term>Healthy control subjects</term><term>Huntington disease imaging</term><term>Huntington disease mutation carriers</term><term>Imaging biomarker</term><term>Important component</term><term>Important role</term><term>Increase sensitivity</term><term>Interhemispheric connections</term><term>Interhemispheric relationships</term><term>Internal medicine</term><term>Iowa</term><term>Iowa city</term><term>Irccs neuromed</term><term>Irccs santa lucia foundation</term><term>Iron concentration</term><term>Iron content</term><term>Large cohort</term><term>Leiden university</term><term>London school</term><term>Longitudinal change</term><term>Magnetic susceptibility</term><term>Matrix size</term><term>Medical genetics</term><term>Medical statistics</term><term>Methodological approach</term><term>Methods children ages</term><term>Monash university</term><term>Multiecho relaxometry</term><term>Mutation carriers</term><term>Nding treatments</term><term>Neurol neurosurg psychiatry september</term><term>Neurology</term><term>Novel segmentation technique</term><term>Parietal lobe</term><term>Posterior tracts</term><term>Premanifest gene carriers</term><term>Premanifest subjects</term><term>Presymptomatic subjects</term><term>Public health</term><term>Putamen</term><term>Rare diseases center</term><term>Regional tissues</term><term>Research purposes</term><term>Same protocol</term><term>Segmentation protocol</term><term>Striatal structure</term><term>Striatal volume</term><term>Study iron distribution</term><term>Tesla siemens scanner</term><term>Total brain tissue</term><term>Total brain tissue volumes</term><term>Tropical medicine</term><term>University college london</term><term>Useful measure</term><term>Ventricular volume</term><term>Volume change</term><term>Volume loss</term><term>Volumetric measurements</term><term>Voxel size</term><term>Washington university</term><term>White matter volume</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Background Research into Huntington's disease (HD) has revealed white-matter loss in individuals more than 10 years prior to predicted disease onset, focused around the striatum, corpus callosum (CC) and posterior white-matter tracts. Degeneration of the CC is of interest since it provides interhemispheric connections to cortical areas known to be affected in HD. Aims This study aims to investigate the utility of volumetric measurements of the CC in HD using a novel segmentation technique, multiple time-points and a large well-characterised cohort. Structure-function relationship in the CC will also be explored. Methods Volumetric 3T MRI from controls, premanifest gene carriers and early HD subjects enrolled in the TRACK-HD study will be analysed at baseline and 24 months. The CC will be delineated using a semi-automated segmentation protocol. Differences in baseline volumes and atrophy rates between groups will be examined, as well as correlations between volume loss and clinical impairment. Results Preliminary analysis of a subset of subjects indicates that early HD subjects have reduced CC volume compared with controls and premanifest subjects (p<0.001). Increased longitudinal CC volume change was found in early HD subjects, compared with controls (p<0.001). Interestingly there was significant difference in longitudinal change between controls and premanifest subjects close to disease onset (p<0.05). This work will be extended to include multi-site data and correlations between atrophy and clinical and cognitive decline. Conclusions Measurement of CC atrophy may have potential as an imaging biomarker for HD and may prove useful for exploring interhemispheric structure-function relationships. Funding Helen Crawford is supported by the CHDI Foundation, a not for profit organisation dedicated to finding treatments for HD.</div></front></TEI><istex><corpusName>bmj</corpusName><keywords><teeft><json:string>neurology</json:string><json:string>putamen</json:string><json:string>iron content</json:string><json:string>iowa city</json:string><json:string>disease onset</json:string><json:string>huntington disease mutation carriers</json:string><json:string>premanifest subjects</json:string><json:string>brain structure</json:string><json:string>british columbia</json:string><json:string>iowa</json:string><json:string>nding treatments</json:string><json:string>university college london</json:string><json:string>increase sensitivity</json:string><json:string>early neurobiological changes</json:string><json:string>medical statistics</json:string><json:string>london school</json:string><json:string>tropical medicine</json:string><json:string>7genetic medicine</json:string><json:string>health sciences centre</json:string><json:string>central manchester university hospitals</json:string><json:string>foundation trust</json:string><json:string>monash university</json:string><json:string>aphp hopital</json:string><json:string>medical genetics</json:string><json:string>striatal structure</json:string><json:string>leiden university</json:string><json:string>background research</json:string><json:string>clinical measures</json:string><json:string>corpus callosum</json:string><json:string>posterior tracts</json:string><json:string>interhemispheric connections</json:string><json:string>cortical areas</json:string><json:string>volumetric measurements</json:string><json:string>novel segmentation technique</json:string><json:string>large cohort</json:string><json:string>premanifest gene carriers</json:string><json:string>segmentation protocol</json:string><json:string>baseline volumes</json:string><json:string>atrophy rates</json:string><json:string>volume loss</json:string><json:string>clinical impairment</json:string><json:string>striatal volume</json:string><json:string>volume change</json:string><json:string>longitudinal change</json:string><json:string>cognitive decline</json:string><json:string>conclusions measurement</json:string><json:string>imaging biomarker</json:string><json:string>interhemispheric relationships</json:string><json:string>funding helen crawford</json:string><json:string>chdi foundation</json:string><json:string>methodological approach</json:string><json:string>cortical alterations</json:string><json:string>neurol neurosurg psychiatry september</json:string><json:string>washington university</json:string><json:string>important component</json:string><json:string>abnormal brain development</json:string><json:string>current study</json:string><json:string>methods children ages</json:string><json:string>research purposes</json:string><json:string>gene nonexpanded</json:string><json:string>healthy control</json:string><json:string>same protocol</json:string><json:string>brain morphology</json:string><json:string>total brain tissue</json:string><json:string>ventricular volume</json:string><json:string>white matter volume</json:string><json:string>cerebral lobes</json:string><json:string>corpus callosal atrophy</json:string><json:string>total brain tissue volumes</json:string><json:string>parietal lobe</json:string><json:string>global measures</json:string><json:string>brain growth</json:string><json:string>regional tissues</json:string><json:string>aberrant brain development</json:string><json:string>important role</json:string><json:string>1ucl institute</json:string><json:string>behavioural parameters</json:string><json:string>healthy control subjects</json:string><json:string>1radiology department</json:string><json:string>irccs santa lucia foundation</json:string><json:string>clinical psychobiology</json:string><json:string>internal medicine</json:string><json:string>public health</json:string><json:string>rare diseases center</json:string><json:string>irccs neuromed</json:string><json:string>huntington disease imaging</json:string><json:string>useful measure</json:string><json:string>study iron distribution</json:string><json:string>iron concentration</json:string><json:string>magnetic susceptibility</json:string><json:string>grey matter</json:string><json:string>globus pallidus</json:string><json:string>presymptomatic subjects</json:string><json:string>cerebral structure</json:string><json:string>mutation carriers</json:string><json:string>early disease stages</json:string><json:string>multiecho relaxometry</json:string><json:string>tesla siemens scanner</json:string><json:string>abstract table</json:string><json:string>matrix size</json:string><json:string>voxel size</json:string></teeft></keywords><author><json:item><name>HE Crawford</name><affiliations><json:string>UCL Institute of Neurology, University College London, London, UK</json:string></affiliations></json:item><json:item><name>NZ Hobbs</name><affiliations><json:string>UCL Institute of Neurology, University College London, London, UK</json:string></affiliations></json:item><json:item><name>J Cole</name><affiliations><json:string>UCL Institute of Neurology, University College London, London, UK</json:string></affiliations></json:item><json:item><name>EM Rees</name><affiliations><json:string>UCL Institute of Neurology, University College London, London, UK</json:string></affiliations></json:item><json:item><name>G Owen</name><affiliations><json:string>UCL Institute of Neurology, University College London, London, UK</json:string></affiliations></json:item><json:item><name>DR Langbehn</name><affiliations><json:string>Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA</json:string><json:string>Department of Biostatistics (Secondary), University of Iowa, Iowa City, Iowa, USA</json:string></affiliations></json:item><json:item><name>C Frost</name><affiliations><json:string>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK</json:string></affiliations></json:item><json:item><name>B Landwehrmeyer</name><affiliations><json:string>Department of Neurology, Ulm University, Ulm, Germany</json:string></affiliations></json:item><json:item><name>R Reilmann</name><affiliations><json:string>Department of Neurology, University of Münster, Münster, Germany</json:string></affiliations></json:item><json:item><name>D Craufurd</name><affiliations><json:string>Genetic Medicine, University of Manchester, Manchester Academic Health Sciences Centre and Central Manchester University Hospitals NHS Foundation Trust, St Mary's Hospital, Manchester, UK</json:string></affiliations></json:item><json:item><name>JC Stout</name><affiliations><json:string>School of Psychology and Psychiatry, Monash University, Victoria, Australia</json:string></affiliations></json:item><json:item><name>A Durr</name><affiliations><json:string>Department of Genetics and Cytogenetics, and INSERM UMR S679, APHP Hôpital de la Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>B Leavitt</name><affiliations><json:string>Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada</json:string></affiliations></json:item><json:item><name>RA Roos</name><affiliations><json:string>Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands</json:string></affiliations></json:item><json:item><name>SJ Tabrizi</name><affiliations><json:string>UCL Institute of Neurology, University College London, London, UK</json:string></affiliations></json:item><json:item><name>RI Scahill</name><affiliations><json:string>UCL Institute of Neurology, University College London, London, UK</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Corpus callosum</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>imaging-biomarker</value></json:item></subject><articleId><json:string>jnnp-2012-303524.83</json:string></articleId><arkIstex>ark:/67375/NVC-C5NHWTJ7-4</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>abstract</json:string></originalGenre><abstract>Background Research into Huntington's disease (HD) has revealed white-matter loss in individuals more than 10 years prior to predicted disease onset, focused around the striatum, corpus callosum (CC) and posterior white-matter tracts. Degeneration of the CC is of interest since it provides interhemispheric connections to cortical areas known to be affected in HD. Aims This study aims to investigate the utility of volumetric measurements of the CC in HD using a novel segmentation technique, multiple time-points and a large well-characterised cohort. Structure-function relationship in the CC will also be explored. Methods Volumetric 3T MRI from controls, premanifest gene carriers and early HD subjects enrolled in the TRACK-HD study will be analysed at baseline and 24 months. The CC will be delineated using a semi-automated segmentation protocol. Differences in baseline volumes and atrophy rates between groups will be examined, as well as correlations between volume loss and clinical impairment. Results Preliminary analysis of a subset of subjects indicates that early HD subjects have reduced CC volume compared with controls and premanifest subjects (p>0.001). Increased longitudinal CC volume change was found in early HD subjects, compared with controls (p>0.001). Interestingly there was significant difference in longitudinal change between controls and premanifest subjects close to disease onset (p>0.05). This work will be extended to include multi-site data and correlations between atrophy and clinical and cognitive decline. Conclusions Measurement of CC atrophy may have potential as an imaging biomarker for HD and may prove useful for exploring interhemispheric structure-function relationships. Funding Helen Crawford is supported by the CHDI Foundation, a not for profit organisation dedicated to finding treatments for HD.</abstract><qualityIndicators><score>5.999</score><pdfWordCount>999</pdfWordCount><pdfCharCount>6717</pdfCharCount><pdfVersion>1.6</pdfVersion><pdfPageCount>1</pdfPageCount><pdfPageSize>595.276 x 793.701 pts</pdfPageSize><refBibsNative>false</refBibsNative><abstractWordCount>264</abstractWordCount><abstractCharCount>1853</abstractCharCount><keywordCount>2</keywordCount></qualityIndicators><title>G03 Corpus callosal atrophy in Huntington's disease</title><corporate><json:item><name>and the TRACK-HD Investigators</name></json:item></corporate><genre><json:string>abstract</json:string></genre><host><title>Journal of Neurology, Neurosurgery & Psychiatry</title><language><json:string>unknown</json:string></language><issn><json:string>0022-3050</json:string></issn><eissn><json:string>1468-330X</json:string></eissn><publisherId><json:string>jnnp</json:string></publisherId><volume>83</volume><issue>Suppl 1</issue><pages><first>A27</first></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2012</json:string></date><geogName></geogName><orgName><json:string>Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands</json:string><json:string>Washington University</json:string><json:string>Monash University</json:string><json:string>Department of Genetics and Cytogenetics</json:string><json:string>Department of Internal Medicine and Public Health</json:string><json:string>University of Barcelona</json:string><json:string>Department of Psychiatry and Clinical Psychobiology</json:string><json:string>Department of Neurology, University of Munster, Munster</json:string><json:string>University of Iowa, Iowa City</json:string><json:string>University of Manchester</json:string><json:string>NHS Foundation Trust, St Mary</json:string><json:string>CHDI Foundation</json:string><json:string>Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada</json:string><json:string>Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA</json:string><json:string>Department of Neurology, Ulm University, Ulm, Germany</json:string><json:string>Rare Diseases Center</json:string><json:string>Radiology Department, IRCCS Santa Lucia Foundation, Rome, Italy</json:string><json:string>University of Florida</json:string><json:string>Department of Biostatistics</json:string><json:string>Department of Medical Statistics, London School of Hygiene and Tropical Medicine</json:string><json:string>Central Manchester University</json:string><json:string>UCL Institute of Neurology, University College London, London, UK</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName></persName><placeName><json:string>Paris</json:string><json:string>Germany</json:string><json:string>Australia</json:string><json:string>UK</json:string><json:string>Victoria</json:string><json:string>Manchester</json:string><json:string>Barcelona</json:string><json:string>France</json:string><json:string>Italy</json:string><json:string>Spain</json:string></placeName><ref_url></ref_url><ref_bibl></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/NVC-C5NHWTJ7-4</json:string></ark><categories><wos><json:string>1 - social science</json:string><json:string>2 - psychiatry</json:string><json:string>1 - science</json:string><json:string>2 - surgery</json:string><json:string>2 - clinical neurology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - neurology & neurosurgery</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Psychiatry and Mental health</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Clinical Neurology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Surgery</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2012</publicationDate><copyrightDate>2012</copyrightDate><doi><json:string>10.1136/jnnp-2012-303524.83</json:string></doi><id>F5CA874DE78DE98E65D05D4283D1B3CC98696C71</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/F5CA874DE78DE98E65D05D4283D1B3CC98696C71/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/F5CA874DE78DE98E65D05D4283D1B3CC98696C71/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/F5CA874DE78DE98E65D05D4283D1B3CC98696C71/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">G03 Corpus callosal atrophy in Huntington's disease</title><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://publisher-list.data.istex.fr">BMJ Publishing Group Ltd</publisher><availability><licence><p>© 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</p></availability><date>2012</date></publicationStmt><notesStmt><note type="abstract" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-HPN7T1Q2-R">abstract</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">G03 Corpus callosal atrophy in Huntington's disease</title><author role="org"><orgName>and the TRACK-HD Investigators</orgName></author><author xml:id="author-0000"><persName><forename type="first">HE</forename><surname>Crawford</surname></persName><affiliation>UCL Institute of Neurology, University College London, London, UK</affiliation></author><author xml:id="author-0001"><persName><forename type="first">NZ</forename><surname>Hobbs</surname></persName><affiliation>UCL Institute of Neurology, University College London, London, UK</affiliation></author><author xml:id="author-0002"><persName><forename type="first">J</forename><surname>Cole</surname></persName><affiliation>UCL Institute of Neurology, University College London, London, UK</affiliation></author><author xml:id="author-0003"><persName><forename type="first">EM</forename><surname>Rees</surname></persName><affiliation>UCL Institute of Neurology, University College London, London, UK</affiliation></author><author xml:id="author-0004"><persName><forename type="first">G</forename><surname>Owen</surname></persName><affiliation>UCL Institute of Neurology, University College London, London, UK</affiliation></author><author xml:id="author-0005"><persName><forename type="first">DR</forename><surname>Langbehn</surname></persName><affiliation>Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA</affiliation><affiliation>Department of Biostatistics (Secondary), University of Iowa, Iowa City, Iowa, USA</affiliation></author><author xml:id="author-0006"><persName><forename type="first">C</forename><surname>Frost</surname></persName><affiliation>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK</affiliation></author><author xml:id="author-0007"><persName><forename type="first">B</forename><surname>Landwehrmeyer</surname></persName><affiliation>Department of Neurology, Ulm University, Ulm, Germany</affiliation></author><author xml:id="author-0008"><persName><forename type="first">R</forename><surname>Reilmann</surname></persName><affiliation>Department of Neurology, University of Münster, Münster, Germany</affiliation></author><author xml:id="author-0009"><persName><forename type="first">D</forename><surname>Craufurd</surname></persName><affiliation>Genetic Medicine, University of Manchester, Manchester Academic Health Sciences Centre and Central Manchester University Hospitals NHS Foundation Trust, St Mary's Hospital, Manchester, UK</affiliation></author><author xml:id="author-0010"><persName><forename type="first">JC</forename><surname>Stout</surname></persName><affiliation>School of Psychology and Psychiatry, Monash University, Victoria, Australia</affiliation></author><author xml:id="author-0011"><persName><forename type="first">A</forename><surname>Durr</surname></persName><affiliation>Department of Genetics and Cytogenetics, and INSERM UMR S679, APHP Hôpital de la Salpêtrière, Paris, France</affiliation></author><author xml:id="author-0012"><persName><forename type="first">B</forename><surname>Leavitt</surname></persName><affiliation>Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada</affiliation></author><author xml:id="author-0013"><persName><forename type="first">RA</forename><surname>Roos</surname></persName><affiliation>Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands</affiliation></author><author xml:id="author-0014"><persName><forename type="first">SJ</forename><surname>Tabrizi</surname></persName><affiliation>UCL Institute of Neurology, University College London, London, UK</affiliation></author><author xml:id="author-0015"><persName><forename type="first">RI</forename><surname>Scahill</surname></persName><affiliation>UCL Institute of Neurology, University College London, London, UK</affiliation></author><idno type="istex">F5CA874DE78DE98E65D05D4283D1B3CC98696C71</idno><idno type="ark">ark:/67375/NVC-C5NHWTJ7-4</idno><idno type="DOI">10.1136/jnnp-2012-303524.83</idno><idno type="href">jnnp-83-A27-1.pdf</idno><idno type="article-id">jnnp-2012-303524.83</idno><idno type="local">jnnp;83/Suppl_1/A27-ce</idno></analytic><monogr><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title><title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title><idno type="pISSN">0022-3050</idno><idno type="eISSN">1468-330X</idno><idno type="publisher-id">jnnp</idno><idno type="PublisherID-hwp">jnnp</idno><idno type="PublisherID-nlm-ta">J Neurol Neurosurg Psychiatry</idno><imprint><publisher>BMJ Publishing Group Ltd</publisher><date type="published" when="2012-09"></date><biblScope unit="volume">83</biblScope><biblScope unit="issue">Suppl 1</biblScope><biblScope unit="page" from="A27">A27</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2012</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Background Research into Huntington's disease (HD) has revealed white-matter loss in individuals more than 10 years prior to predicted disease onset, focused around the striatum, corpus callosum (CC) and posterior white-matter tracts. Degeneration of the CC is of interest since it provides interhemispheric connections to cortical areas known to be affected in HD. Aims This study aims to investigate the utility of volumetric measurements of the CC in HD using a novel segmentation technique, multiple time-points and a large well-characterised cohort. Structure-function relationship in the CC will also be explored. Methods Volumetric 3T MRI from controls, premanifest gene carriers and early HD subjects enrolled in the TRACK-HD study will be analysed at baseline and 24 months. The CC will be delineated using a semi-automated segmentation protocol. Differences in baseline volumes and atrophy rates between groups will be examined, as well as correlations between volume loss and clinical impairment. Results Preliminary analysis of a subset of subjects indicates that early HD subjects have reduced CC volume compared with controls and premanifest subjects (p<0.001). Increased longitudinal CC volume change was found in early HD subjects, compared with controls (p<0.001). Interestingly there was significant difference in longitudinal change between controls and premanifest subjects close to disease onset (p<0.05). This work will be extended to include multi-site data and correlations between atrophy and clinical and cognitive decline. Conclusions Measurement of CC atrophy may have potential as an imaging biomarker for HD and may prove useful for exploring interhemispheric structure-function relationships. Funding Helen Crawford is supported by the CHDI Foundation, a not for profit organisation dedicated to finding treatments for HD.</p></abstract><textClass><keywords scheme="keyword"><list><head>keywords</head><item><term>Corpus callosum</term></item><item><term>imaging-biomarker</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2012-09">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2017-10-17">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/F5CA874DE78DE98E65D05D4283D1B3CC98696C71/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus bmj" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="no"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" URI="archivearticle.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="abstract"><front><journal-meta><journal-id journal-id-type="hwp">jnnp</journal-id><journal-id journal-id-type="nlm-ta">J Neurol Neurosurg Psychiatry</journal-id><journal-id journal-id-type="publisher-id">jnnp</journal-id><journal-title>Journal of Neurology, Neurosurgery & Psychiatry</journal-title><abbrev-journal-title abbrev-type="publisher">J Neurol Neurosurg Psychiatry</abbrev-journal-title><abbrev-journal-title>J Neurol Neurosurg Psychiatry</abbrev-journal-title><issn pub-type="ppub">0022-3050</issn><issn pub-type="epub">1468-330X</issn><publisher><publisher-name>BMJ Publishing Group Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">jnnp-2012-303524.83</article-id><article-id pub-id-type="doi">10.1136/jnnp-2012-303524.83</article-id><article-id pub-id-type="other">jnnp;83/Suppl_1/A27-ce</article-id><article-id pub-id-type="other">jnnp;jnnp-2012-303524.83</article-id><article-id pub-id-type="other">A27.1</article-id><article-id pub-id-type="other">jnnp-2012-303524.83</article-id><article-categories><subj-group subj-group-type="heading"><subject>Imaging</subject></subj-group><series-title>Imaging</series-title></article-categories><title-group><article-title>G03 Corpus callosal atrophy in Huntington's disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Crawford</surname><given-names>HE</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hobbs</surname><given-names>NZ</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cole</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rees</surname><given-names>EM</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Owen</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Langbehn</surname><given-names>DR</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Frost</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Landwehrmeyer</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Reilmann</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Craufurd</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Stout</surname><given-names>JC</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Durr</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Leavitt</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Roos</surname><given-names>RA</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Tabrizi</surname><given-names>SJ</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Scahill</surname><given-names>RI</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><collab>and the TRACK-HD Investigators</collab></contrib></contrib-group><aff id="aff1"><label>1</label>UCL Institute of Neurology, University College London, London, UK</aff><aff id="aff2"><label>2</label>Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA</aff><aff id="aff3"><label>3</label>Department of Biostatistics (Secondary), University of Iowa, Iowa City, Iowa, USA</aff><aff id="aff4"><label>4</label>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK</aff><aff id="aff5"><label>5</label>Department of Neurology, Ulm University, Ulm, Germany</aff><aff id="aff6"><label>6</label>Department of Neurology, University of Münster, Münster, Germany</aff><aff id="aff7"><label>7</label>Genetic Medicine, University of Manchester, Manchester Academic Health Sciences Centre and Central Manchester University Hospitals NHS Foundation Trust, St Mary's Hospital, Manchester, UK</aff><aff id="aff8"><label>8</label>School of Psychology and Psychiatry, Monash University, Victoria, Australia</aff><aff id="aff9"><label>9</label>Department of Genetics and Cytogenetics, and INSERM UMR S679, APHP Hôpital de la Salpêtrière, Paris, France</aff><aff id="aff10"><label>10</label>Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada</aff><aff id="aff11"><label>11</label>Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands</aff><pub-date pub-type="ppub"><month>9</month><year>2012</year></pub-date><volume>83</volume><volume-id pub-id-type="other">83</volume-id><volume-id pub-id-type="other">83</volume-id><issue>Suppl 1</issue><issue-id pub-id-type="other">jnnp;83/Suppl_1</issue-id><issue-id pub-id-type="other" content-type="supplement">Suppl_1</issue-id><issue-id pub-id-type="other">83/Suppl_1</issue-id><issue-title>European Huntington's Disease Network 2012 plenary meeting, Stockholm, Sweden, 14—16 September 2012</issue-title><fpage seq="1">A27</fpage><permissions><copyright-statement>© 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</copyright-statement><copyright-year>2012</copyright-year></permissions><self-uri content-type="pdf" xlink:role="full-text" xlink:href="jnnp-83-A27-1.pdf"></self-uri><abstract><sec><title>Background</title><p>Research into Huntington's disease (HD) has revealed white-matter loss in individuals more than 10 years prior to predicted disease onset, focused around the striatum, corpus callosum (CC) and posterior white-matter tracts. Degeneration of the CC is of interest since it provides interhemispheric connections to cortical areas known to be affected in HD.</p></sec><sec><title>Aims</title><p>This study aims to investigate the utility of volumetric measurements of the CC in HD using a novel segmentation technique, multiple time-points and a large well-characterised cohort. Structure-function relationship in the CC will also be explored.</p></sec><sec><title>Methods</title><p>Volumetric 3T MRI from controls, premanifest gene carriers and early HD subjects enrolled in the TRACK-HD study will be analysed at baseline and 24 months. The CC will be delineated using a semi-automated segmentation protocol. Differences in baseline volumes and atrophy rates between groups will be examined, as well as correlations between volume loss and clinical impairment.</p></sec><sec><title>Results</title><p>Preliminary analysis of a subset of subjects indicates that early HD subjects have reduced CC volume compared with controls and premanifest subjects (p<0.001). Increased longitudinal CC volume change was found in early HD subjects, compared with controls (p<0.001). Interestingly there was significant difference in longitudinal change between controls and premanifest subjects close to disease onset (p<0.05). This work will be extended to include multi-site data and correlations between atrophy and clinical and cognitive decline.</p></sec><sec><title>Conclusions</title><p>Measurement of CC atrophy may have potential as an imaging biomarker for HD and may prove useful for exploring interhemispheric structure-function relationships.</p></sec><sec><title>Funding</title><p>Helen Crawford is supported by the CHDI Foundation, a not for profit organisation dedicated to finding treatments for HD.</p></sec></abstract><kwd-group><kwd>Corpus callosum</kwd><kwd>imaging-biomarker</kwd></kwd-group></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>G03 Corpus callosal atrophy in Huntington's disease</title><partName>Imaging</partName></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>G03 Corpus callosal atrophy in Huntington's disease</title><partName>Imaging</partName></titleInfo><name type="corporate"><namePart>and the TRACK-HD Investigators</namePart></name><name type="personal"><namePart type="given">HE</namePart><namePart type="family">Crawford</namePart><affiliation>UCL Institute of Neurology, University College London, London, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">NZ</namePart><namePart type="family">Hobbs</namePart><affiliation>UCL Institute of Neurology, University College London, London, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Cole</namePart><affiliation>UCL Institute of Neurology, University College London, London, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EM</namePart><namePart type="family">Rees</namePart><affiliation>UCL Institute of Neurology, University College London, London, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Owen</namePart><affiliation>UCL Institute of Neurology, University College London, London, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">DR</namePart><namePart type="family">Langbehn</namePart><affiliation>Department of Psychiatry, University of Iowa, Iowa City, Iowa, USA</affiliation><affiliation>Department of Biostatistics (Secondary), University of Iowa, Iowa City, Iowa, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Frost</namePart><affiliation>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Landwehrmeyer</namePart><affiliation>Department of Neurology, Ulm University, Ulm, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Reilmann</namePart><affiliation>Department of Neurology, University of Münster, Münster, Germany</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Craufurd</namePart><affiliation>Genetic Medicine, University of Manchester, Manchester Academic Health Sciences Centre and Central Manchester University Hospitals NHS Foundation Trust, St Mary's Hospital, Manchester, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JC</namePart><namePart type="family">Stout</namePart><affiliation>School of Psychology and Psychiatry, Monash University, Victoria, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Durr</namePart><affiliation>Department of Genetics and Cytogenetics, and INSERM UMR S679, APHP Hôpital de la Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Leavitt</namePart><affiliation>Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RA</namePart><namePart type="family">Roos</namePart><affiliation>Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SJ</namePart><namePart type="family">Tabrizi</namePart><affiliation>UCL Institute of Neurology, University College London, London, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RI</namePart><namePart type="family">Scahill</namePart><affiliation>UCL Institute of Neurology, University College London, London, UK</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="abstract" displayLabel="abstract" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-HPN7T1Q2-R">abstract</genre><originInfo><publisher>BMJ Publishing Group Ltd</publisher><dateIssued encoding="w3cdtf">2012-09</dateIssued><copyrightDate encoding="w3cdtf">2012</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract>Background Research into Huntington's disease (HD) has revealed white-matter loss in individuals more than 10 years prior to predicted disease onset, focused around the striatum, corpus callosum (CC) and posterior white-matter tracts. Degeneration of the CC is of interest since it provides interhemispheric connections to cortical areas known to be affected in HD. Aims This study aims to investigate the utility of volumetric measurements of the CC in HD using a novel segmentation technique, multiple time-points and a large well-characterised cohort. Structure-function relationship in the CC will also be explored. Methods Volumetric 3T MRI from controls, premanifest gene carriers and early HD subjects enrolled in the TRACK-HD study will be analysed at baseline and 24 months. The CC will be delineated using a semi-automated segmentation protocol. Differences in baseline volumes and atrophy rates between groups will be examined, as well as correlations between volume loss and clinical impairment. Results Preliminary analysis of a subset of subjects indicates that early HD subjects have reduced CC volume compared with controls and premanifest subjects (p<0.001). Increased longitudinal CC volume change was found in early HD subjects, compared with controls (p<0.001). Interestingly there was significant difference in longitudinal change between controls and premanifest subjects close to disease onset (p<0.05). This work will be extended to include multi-site data and correlations between atrophy and clinical and cognitive decline. Conclusions Measurement of CC atrophy may have potential as an imaging biomarker for HD and may prove useful for exploring interhemispheric structure-function relationships. Funding Helen Crawford is supported by the CHDI Foundation, a not for profit organisation dedicated to finding treatments for HD.</abstract><subject><genre>keywords</genre><topic>Corpus callosum</topic><topic>imaging-biomarker</topic></subject><relatedItem type="host"><titleInfo><title>Journal of Neurology, Neurosurgery & Psychiatry</title></titleInfo><titleInfo type="abbreviated"><title>J Neurol Neurosurg Psychiatry</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0022-3050</identifier><identifier type="eISSN">1468-330X</identifier><identifier type="PublisherID">jnnp</identifier><identifier type="PublisherID-hwp">jnnp</identifier><identifier type="PublisherID-nlm-ta">J Neurol Neurosurg Psychiatry</identifier><part><date>2012</date><detail type="title"><title>European Huntington's Disease Network 2012 plenary meeting, Stockholm, Sweden, 14—16 September 2012</title></detail><detail type="volume"><caption>vol.</caption><number>83</number></detail><detail type="issue"><caption>no.</caption><number>Suppl 1</number></detail><extent unit="pages"><start>A27</start></extent></part></relatedItem><identifier type="istex">F5CA874DE78DE98E65D05D4283D1B3CC98696C71</identifier><identifier type="ark">ark:/67375/NVC-C5NHWTJ7-4</identifier><identifier type="DOI">10.1136/jnnp-2012-303524.83</identifier><identifier type="href">jnnp-83-A27-1.pdf</identifier><identifier type="ArticleID">jnnp-2012-303524.83</identifier><identifier type="local">jnnp;83/Suppl_1/A27-ce</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</recordContentSource><recordOrigin>© 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/document/F5CA874DE78DE98E65D05D4283D1B3CC98696C71/metadata/json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E31 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002E31 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:F5CA874DE78DE98E65D05D4283D1B3CC98696C71
|texte= G03 Corpus callosal atrophy in Huntington's disease
}}
| This area was generated with Dilib version V0.6.33. |  |